


R₅ is X or -C₁-C₆ alkylene-X, wherein X is selected from the group consisting of:

(i) phenyl;


(ii) heteroaryl including from 5 to 6 ring atoms wherein 1, 2, or 3 of the ring atoms are independently selected from the group consisting of N, NH, N(C₁-C₃ alkyl), O, and S; and

5 (iii) heterocyclyl including from 3 to 6 ring atoms wherein 1, 2, or 3 of the ring atoms are independently selected from the group consisting of N, NH, N(C₁-C₃ alkyl), O, and S;

wherein R₅ is optionally substituted with ; and

R₆ is selected from the group consisting of H, halogen, hydroxyl, cyano, -O-C(O)-C₁-C₆ alkyl, C₁-C₆ alkyl, or C₁-C₆ alkoxy.

10 **[0008a]** In one aspect of the present disclosure, there is provided a compound represented by formula I:



or a pharmaceutically acceptable salt thereof, wherein

R_b is selected from the group consisting of H, halogen, hydroxyl, cyano or C₁-C₆ alkyl;

15 R₁ is H or C₁-C₆ alkyl;

R₂ is H or C₁-C₆ alkyl;

R₃ is selected from the group consisting of H, C₁-C₆ alkyl and a nitrogen protecting group;

R₄ is H or C₁-C₆ alkyl;

20 R₅ is X or -C₁-C₆ alkylene-X, wherein X is selected from the group consisting of:

(i) phenyl;


(ii) heteroaryl including from 5 to 6 ring atoms wherein 1, 2, or 3 of the ring atoms are independently selected from the group consisting of N, NH, N(C₁-C₃ alkyl), O, and S; and

(iii) heterocyclyl including from 3 to 6 ring atoms wherein 1, 2, or 3 of the ring atoms are independently selected from the group consisting of N, NH, N(C₁-C₃ alkyl), O,

and S; wherein R₅ is optionally substituted with ; and

R₆ is selected from the group consisting of H, halogen, hydroxyl, cyano, -O-C(O)-C₁-C₆ alkyl, C₁-C₆ alkyl, or C₁-C₆ alkoxy.

[0008b] In another aspect of the present disclosure, there is provided a compound represented by formula I:



and pharmaceutically acceptable salts, stereoisomers, and N-oxides thereof, wherein

R_b is selected from the group consisting of H, halogen, hydroxyl, cyano or C₁-C₆ alkyl;

R₁ is H or C₁-C₆ alkyl;

R₂ is H or C₁-C₆ alkyl;

R₃ is selected from the group consisting of H, C₁-C₆ alkyl and a nitrogen protecting group;

R₄ is H or C₁-C₆ alkyl;

R₅ is X or -C₁-C₆ alkylene-X, wherein X is selected from the group consisting of phenyl, a 4- to 6-membered heteroaryl ring having 1, 2, or 3 heteroatoms selected from O, S, or N, or a 4- to 6-membered heterocyclyl ring having 1, 2, or 3 heteroatoms


selected from O, S, or N, and wherein R₅ is optionally substituted with ; and

R₆ is selected from the group consisting of H, halogen, hydroxyl, cyano, -O-C(O)-C₁-C₆ alkyl, C₁-C₆ alkyl, or C₁-C₆ alkoxy.

[0009] In another aspect, there is provided a compound represented by formula II:

What is claimed is:

1. A compound represented by formula I:



or a pharmaceutically acceptable salt thereof, wherein

R_b is selected from the group consisting of H, halogen, hydroxyl, cyano or C₁-C₆ alkyl;

R₁ is H or C₁-C₆ alkyl;

R₂ is H or C₁-C₆ alkyl;

R₃ is selected from the group consisting of H, C₁-C₆ alkyl and a nitrogen protecting group;

R₄ is H or C₁-C₆ alkyl;

R₅ is X or -C₁-C₆ alkylene-X, wherein X is selected from the group consisting of:

(i) phenyl;

(ii) heteroaryl including from 5 to 6 ring atoms wherein 1, 2, or 3 of the ring atoms are independently selected from the group consisting of N, NH, N(C₁-C₃ alkyl), O, and S; and


(iii) heterocyclyl including from 3 to 6 ring atoms wherein 1, 2, or 3 of the ring atoms are independently selected from the group consisting of N, NH, N(C₁-C₃ alkyl), O,





and S; wherein R₅ is optionally substituted with ; and




R₆ is selected from the group consisting of H, halogen, hydroxyl, cyano, -O-C(O)-C₁-C₆ alkyl, C₁-C₆ alkyl, or C₁-C₆ alkoxy.




2. The compound of claim 1, wherein R₁ is H.
3. The compound of claim 1 or 2, wherein R₂ is H.
4. The compound of any one of claims 1-3, wherein R₃ is H.
5. The compound of any one of claims 1-3, wherein R₃ is a nitrogen protecting group.





20. The compound of any one of claims 1-11, wherein R_5 is $-C_1-C_6$ alkylene-X.
21. The compound of any one of claims 1-11, wherein R_5 is $-C_1-C_2$ alkylene-X.
22. The compound of claim 21 or 22, wherein R_5 is substituted with $-\text{CH}(R_4)(R_6)$.
23. The compound of claim 22, wherein R_5 is substituted on the alkylene portion with $-\text{CH}(R_4)(R_6)$.
24. The compound of claim 23, wherein R_5 has the formula $-\text{CH}(\text{CHR}_4\text{R}_6)\text{-X}$.
25. The compound of any one of claims 22-24, wherein R_4 is C_1-C_6 alkyl.
26. The compound of any one of claims 22-25, wherein R_4 is methyl.
27. The compound of any one of claims 22-26, wherein R_6 is selected from the group consisting of hydroxyl, $-\text{O}-\text{C}(\text{O})-\text{C}_1-\text{C}_6$ alkyl, and C_1-C_6 alkoxy.
28. The compound of claim 27, wherein R_6 is hydroxyl.
29. The compound of claim 20 or 21, wherein X is heteroaryl including from 5 to 6 ring atoms wherein 1, 2, or 3 of the ring atoms are independently selected from the group consisting of N, NH, $\text{N}(\text{C}_1-\text{C}_3 \text{ alkyl})$, O, and S.
30. The compound of any one of claims 20-22, wherein X is selected from the group consisting of 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, pyridyl, and pyrimidinyl.
31. The compound of any one of claims 1-30, wherein R_b is H.
32. The compound of claim 1, wherein the compound is selected from the compounds delineated in Table 1 the following table:


















33. A pharmaceutical composition comprising a compound of any one of claims 1-32, and a pharmaceutically acceptable excipient.
34. The pharmaceutical composition of claim 33, suitable for oral administration.
35. The pharmaceutical composition of claim 33, suitable for intravenous administration.
36. Use of a compound of any one of claims 1-32 in the manufacture of a medicament for treating depression, Alzheimer's disease, attention deficit disorder, schizophrenia, or anxiety, in a patient in need thereof.

37. A compound represented by formula I:



and pharmaceutically acceptable salts, stereoisomers, and N-oxides thereof, wherein

R_b is selected from the group consisting of H, halogen, hydroxyl, cyano or C_1 - C_6 alkyl;

R_1 is H or C_1 - C_6 alkyl;

R_2 is H or C_1 - C_6 alkyl;

R_3 is selected from the group consisting of H, C_1 - C_6 alkyl and a nitrogen protecting group;

R_4 is H or C_1 - C_6 alkyl;

R_5 is X or $-C_1$ - C_6 alkylene-X, wherein X is selected from the group consisting of phenyl, a 4- to 6-membered heteroaryl ring having 1, 2, or 3 heteroatoms selected from O, S, or N, or a 4- to 6-membered heterocyclyl ring having 1, 2, or 3 heteroatoms

selected from O, S, or N, and wherein R_5 is optionally substituted with ; and

R_6 is selected from the group consisting of H, halogen, hydroxyl, cyano, $-O-C(O)-C_1$ - C_6 alkyl, C_1 - C_6 alkyl, or C_1 - C_6 alkoxy.

38. The compound of claim 37, wherein R_1 is H.

39. The compound of claim 37 or 38, wherein R_2 is H.

40. The compound of any one of claims 37-39, wherein R_3 is H.

41. The compound of any one of claims 37-40, wherein R_4 is C_1 - C_6 alkyl.

42. The compound of any one of claims 37-40, wherein R_4 is methyl.

43. The compound of any one of claims 37-42, wherein R_b is H.

44. The compound of any one of claims 37-43, wherein R_5 is X, and wherein X is a 5- to 6-membered heteroaryl ring selected from the group consisting of azetidine, pyrrolidine,